Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
Jason B. Gibbons, PhD
Advertisement
Articles by Jason B. Gibbons, PhD
The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Medicare beneficiaries attributed to small practices in accountable care organizations (ACOs) achieve greater savings than beneficiaries attributed to large practices in ACOs.
Advertisement
Latest Updated Articles
- Humira: The First $20 Billion Drug
February 8th 2023
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
4
Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes
5